Series B Cell Therapy Company
Consolidated trial systems and reduced reconciliation burden
Context
A Series B cell therapy company with 3 active trials across Phase 1 and 2, using separate vendors for EDC, RTSM, and safety systems.
Challenge
Fragmented vendor landscape created delays, duplicate workflows, and weak visibility across trial operations. Data reconciliation between systems consumed 20+ hours per week, and site staff struggled with multiple logins and inconsistent interfaces.
Approach
Conducted a comprehensive architecture audit, selected a unified platform strategy, and designed a staged migration plan across active studies. Prioritised data model alignment and phased vendor transition to minimise disruption.
Outcome
Reduced data reconciliation cycle time by 60%, eliminated two redundant vendor contracts saving $180K annually, and improved site staff satisfaction scores by 40%.